Skip to main content
Equibles
BICX logo

BICX · BioCorRx Inc.

Track BICX — free

Use BICX with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$0.21 +0.01 (+4.48%) At close · Aug 31
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“As of June 30, 2026, the Company had cash of $21,237 and working capital deficit of $8,231,326. During the six months ended June 30, 2026, the Company used net cash in operating activities of $873,260. The Company has incurred net losses since inception. These conditions raise substantial doubt about the Company's ability to continue as a going concern for the next twelve-month period since the date of the financial statements were issued.”
View the 10-Q filed Aug 14, 2026
Customer concentration — top 2 customers 100% of revenue

2 customers — 100% of revenue (three months ended June 30, 2026)

“The Company's revenues earned from sale of products and services for the three months ended June 30, 2026 included 100% from two customers of the Company's total revenues.”

2 customers — 99% of revenue (three months ended June 30, 2025)

“The Company's revenues earned from sale of products and services for the three months ended June 30, 2025 included 99% from two customers of the Company's total revenues.”
View the 10-Q filed Aug 14, 2026
Market Cap
$5.98M
Shares
29.76M

BICX metrics

52 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.21
Market cap
$5.98M

Price action

19 metrics
Price change (1W)
-5.8%
Price change (30D)
-23.6%
Price change (3M)
-36.4%
Price change (6M)
-30.9%
Price change (YTD)
-27.8%
Price change (1Y)
-19.8%
Trailing year
Price change (5Y)
-94.2%
52-week high
$0.50
52-week low
$0.16
Change from 52-week high
-58.0%
Change from 52-week low
+31.2%
Annualized volatility
331.2%
Beta
-1.2
RSI (14D)
41.3
Price vs SMA 50
-34.4%
Price vs SMA 200
-40.7%
Avg volume (3M)
5,339
Relative volume
0.1
Average dollar volume
$1,509

Company

3 metrics
Sector
Healthcare
Industry
Medical Care Facilities
Shares outstanding
29.76M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
7.6×
reciprocal yield 13.2%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-52.7%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
64.4×
reciprocal yield 1.6%
EV / revenue historical average (5Y)
64.4×
reciprocal yield 1.6%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
-623.1%
Trailing 12 months
Net margin
-400.6%
Gross profit (TTM)
$183,109
Operating profit (TTM)
−$4.90M
Net income (TTM)
−$3.15M
Trailing 12 months
Diluted EPS (TTM)
$-0.12
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-1.20

Growth

11 metrics
Revenue growth YoY
-50.6%
Year over year
Net income growth YoY
—
Revenue (TTM)
$786,616
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+71.8%
Year over year · more shares
Revenue CAGR (3Y)
+55.1%
Revenue CAGR (5Y)
+45.4%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-165.2%
Debt / equity
—
Current ratio
0.1
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
0.1
Interest coverage
-30.5
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$21,237
Total assets
$1.91M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$2.36M
Capital expenditures (TTM)
—
R&D (TTM)
$2.37M
SG&A (TTM)
$3.15M
Stock compensation (TTM)
—
R&D / revenue
301.9%
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
—
13F filer change QoQ
—
Institutional ownership
—

Short interest

3 metrics
Short interest
—
Latest settlement
Days to cover
—
Short-squeeze score
—

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1443863 Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)